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A B S T R A C T
Background: The World Health Organization (WHO) recommends the use of adjunctive urine
lipopolysaccharide lipoarabinomannan (LAM) testing in hospitalized HIV-infected persons with
suspected tuberculosis (TB) and a CD4 count <100 cells/ml. However, the recommendation is conditional,
and uptake by individual treatment programmes depends on perceived additional benefit. The aim of this
study was to determine whether adjunctive LAM testing has additional clinical benefits including a
reduction in healthcare-related use of resources.
Methods: A post hoc analysis was performed of a published multicentre, multi-country, randomized
controlled trial that showed an approximate 20% mortality benefit in HIV-infected hospitalized patients
who underwent adjunctive LAM testing as part of their diagnostic workup. In that parent study, adult
HIV-infected hospitalized patients with suspected TB (n = 2528) were randomly allocated to either
routine diagnostics (smear microscopy, Xpert MTB/RIF, and culture; n = 1271), or routine diagnostics plus
adjunctive urine LAM testing (n = 1257). Data were further analyzed to determine whether there were
other potential benefits of LAM usage based on CD4 count and illness severity. Aspects evaluated
included: (1) the reduction in number of diagnostic sputum samples tested, (2) the utilization of
additional imaging, (3) disease resolution based on follow-up signs and symptoms of illness severity, and
(4) the reduction in hospital readmission.
Results: Adjuvant LAM did not reduce the number of diagnostic sputum samples requested, the need for
additional imaging, or the hospital readmission rate. However, adjunctive LAM was associated with a
more rapid rate of disease resolution (dyspnoea) in the severely ill subgroup. Higher LAM grade (grades 4
and 5), compared to lower grade positivity (3), was associated with lower use of ultrasound, lower
Karnofsky performance score, lower CD4 cell count, and shorter time to culture positivity.
Conclusions: Although, adjunct LAM was associated with a mortality benefit in the parent study, no
benefit could be demonstrated in the secondary analysis with respect to the number of diagnostic
sputum samples requested, the use of additional imaging, or hospital readmission rates. However, given
the limitations of the present study, further appropriately designed studies are required to determine the
effect of adjunct urine LAM on the utilization of healthcare resources.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) is a major cause of mortality and morbidity in
HIV-infected patients (Cohen et al., 2010; Lawn et al., 2013; Dheda
et al., 2016). A major limitation of current mainstream TB
diagnostic tests is their resource intensiveness and the turnaround
time of tests (Wasserman and Meintjes, 2014). Furthermore, it is
often difficult to obtain sputum samples from HIV-infected
patients and the production of aerosols is a potential danger to
healthcare workers, hospital staff, and other hospitalized patients
(Wasserman and Meintjes, 2014).
Point-of-care urine testing offers rapid test turnaround times
and is less resource-intensive than currently used TB diagnostic
tests (Drain et al., 2014). Lipopolysaccharide lipoarabinomannan
(LAM) testing at the point of care has been shown to have mortality
benefit in HIV-infected patients with advanced immunosuppres-
sion, likely because of a shorter time to treatment and greaterFigure 1. Study overviewproportion of patients receiving anti-TB treatment (Peter et al.,
2016). Furthermore, LAM testing may be useful for prognostica-
tion, since a positive result is associated with higher mortality
(Gupta-Wright et al., 2016).
Thus, the World Health Organization (WHO) recommends the
use of adjunctive urine LAM testing in HIV-infected persons with a
CD4 count <100 cells/ml or in those who are seriously ill (WHO,
2015). However, the recommendation is conditional, and uptake by
individual treatment programmes depends on perceived addition-
al benefit. Additional potential benefits may include a reduction in
number of sputum sample requests, additional imaging (beyond X-
rays), signs and symptoms of illness (dyspnoea, night sweats, pain,
and haemoptysis), the use of empiric antibiotics, and hospital
readmission. The reduction in use of healthcare resources (anti-
biotics, imaging, sputum testing, readmission rates, etc.) may have
cost savings. This may inform resource allocation and public health
strategy and impact decisions about the rollout and use of urine and flow diagram.
Table 1
Radiographic imaging obtained in all countries combined (South Africa, Zimbabwe,
Tanzania, and Zambia) for those who did and did not receive adjunctive LAM testing.
No LAM Adjunctive LAM p-Value
Ultrasound
Entire cohort 311/1162 (26.8%) 335/1163 (28.8%) 0.272
CD4 cells >100 128/510 (25.1%) 129/469 (27.5%) 0.392
CD4 cells 50–100 49/195 (25.1%) 52/185 (28.1%) 0.511
CD4 cells <50 89/388 (22.9%) 96/429 (22.4%) 0.848
Severely ill 168/534 (31%) 172/522 (33%) 0.7577
CT scan
Entire cohort 46/1204 (3.8%) 40/1187 (3.4%) 0.554
CD4 cells >100 22/522 (4.2%) 23/484 (4.7%) 0.680
CD4 cells 50–100 10/196 (5.1%) 6/189 (3.2%) 0.343
CD4 cells <50 10/400 (2.5%) 10/432 (2%) 0.862
Severely ill 13/471 (3%) 16/471 (3%) 0.7187
LAM, lipopolysaccharide lipoarabinomannan; CT, computed tomography.
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LAM usage are conditional. However, there are hardly any data
about the impact of adjunctive urine LAM on healthcare resource
utilization. This study aimed to address the aforementioned
knowledge gap. It was hypothesized that adjunctive LAM testing
would reduce the number of sputum samples, reduce utilization of
additional imaging, quicken disease resolution (based on follow-
up signs and symptoms of illness severity), and reduce hospital
readmission.
Methods
Study design and conduct
This study analyzed data from a published pragmatic,
randomized, parallel-arm, multicentre, multi-country study that
investigated the utility of adjunctive LAM testing in HIV-infected
hospitalized patients in South Africa, Tanzania, Zambia, and
Zimbabwe (Peter et al., 2016). Patients were randomized to a
LAM-guided or conventional arm, thus functionally eliminating
the bias introduced by physician practice.
The study received regulatory and ethical clearance from the
relevant authorities and was aligned with the Declaration of
Helsinki. Informed consent was received from all participants in
their first language. This trial is registered with Clinicaltrials.gov,
number NCT01770730.
Study patients and enrolment criteria
Patients admitted to 10 urban or peri-urban hospitals in South
Africa, Tanzania, Zambia, and Zimbabwe were screened for study
inclusion. The inclusion criteria were (1) HIV-infected persons; (2)
at least one of the following symptoms: current fever or cough,
drenching night sweats, and self-reported loss of weight; (3) illness
severe enough to necessitate hospitalization; (4) age 18 years; (5)
granting of informed consent. The exclusion criteria were: (1)
persons not infected with HIV, (2) patients receiving any anti-TB
medication in the 60 days prior to testing, and (3) unable to provide
at least 30 ml of urine.
Procedures and clinical management
On enrolment of patients, a spot urine specimen (>30 ml) or a
spot catheter sample was collected. Alere Determine TB LAM Ag
lateral flow strip testing was performed at the bedside for patients
allocated to the LAM testing arm.
Patients were asked to expectorate a minimum of two sputum
samples for routine TB diagnosis. For patients unable to self-
expectorate, sputum was induced. A clinical assessment and chest
X-ray facilities were available in most cases. Additional radiology
(e.g., ultrasound or computed tomography (CT) scanning) and non-
sputum sampling were differentially available in study hospitals;
the request for these investigations was at the discretion of the
attending clinical team.
The attending clinical team made all decisions regarding
patient therapy, use of additional radiology, request of non-
sputum sampling, and initiation of anti-TB treatment and the
timing thereof, including acting upon the LAM test results.
Database and analysis
A total of 8728 patients were screened and 2659 eligible
patients were randomized; 2528 were included in the final
analysis (1257 in the LAM group and 1271 in the non-LAM group).
Data were analyzed to determine whether there were other
potential benefits (beyond mortality) of LAM usage in all studyparticipants and in subgroups of patients with a CD4 count <50,
50–100, and >100 cells/ml, and severely ill (respiratory rate >30,
heart rate >120, temperature >39 C). Research staff assessed
symptoms at 8 weeks after randomization (within a range of 14
days). Figure 1 outlines the study overview.
Statistical methods
The median and interquartile range (IQR) were calculated for
continuous variables and the frequency (percentage) for categori-
cal variables. Continuous variables were compared with the
Wilcoxon rank sum test and categorical variables with the Chi-
square test. When comparing the adjuvant LAM group to the non-
LAM group, quantitative and qualitative variables were compared
using the Mann–Whitney U-test and the Chi-square test or Fisher’s
exact test, respectively. A Chi-square test was performed to
determine whether LAM grade correlated with mortality, and the
Mann–Whitney test was used to determine whether adjunctive
LAM reduced the number of sputum samples collected. Logistic
regression analysis included variables that were significantly
associated with the LAM grade. A significance value of p < 0.05 was
used. Statistical analyses were conducted in Stata (version 13).
Results
Adjunctive LAM and sputum samples
In patients receiving adjuvant LAM, there was no reduction in
the number of sputum samples requested by clinicians (1034 vs.
1019, p = 0.7680).
Use of additional imaging
In patients receiving adjuvant LAM, there was no reduction in
the use of additional imaging (ultrasonography and CT) in the
entire cohort or in the subgroups (CD4 cell count >100 cells/ml,
50–100 cells/ml, and <50 cells/ml, and severely ill patients).
Stratification by country did not show a reduction in usage of
ultrasound or CT scans. A total of 85 CT scans were performed (52 of
the head, 13 of the chest, 13 of the abdomen, and 7 unspecified).
South Africa used the most additional imaging. The aforemen-
tioned results are presented in Tables 1 and 2.
Disease resolution based on follow-up signs and symptoms of illness
During follow-up, there were significantly fewer patients with
dyspnoea in the severely ill group receiving adjuvant LAM. In
patients receiving adjuvant LAM, there was no reduction in
Table 2
Ultrasound and computed tomography utilization stratified by country.
Country Adjunctive LAM No adjunctive LAM p-Valuea
Number of US/number of patients Number of US/number of patients
US
South Africa 111/254 (44%) 110/253 (43%) 1.000
Zimbabwe 9/460 (2%) 4/460 (1%) 0.263
Tanzania 0/205 (0%) 1/211 (0%) 1.000
Zambia 215/338 (64%) 196/347 (56%) 0.0614
Country Adjunctive LAM No adjunctive LAM p-Valuea
Number of CT/number of patients Number of CT/number of patients
CT scan
South Africa 38/254 (15%) 43/253 (17%) 0.547
Zimbabwe 1/460 (0.2%) 1/460 (0.2%) 1.000
Tanzania 0/204 (0%) 0/209 (0%) –
Zambia 1/269 (0.4%) 2/282 (1%) 1.000
LAM, lipopolysaccharide lipoarabinomannan; US, ultrasound; CT, computed tomography.
a Fisher’s exact test.
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or in any of the CD4 cell count subgroups (>100 cells/ml, 50–100
cells/ml, and <50 cells/ml). The aforementioned results are
presented in Table 3.Table 3
Symptoms at follow-up for the group receiving LAM versus the group not receiving
LAM. The groups were stratified into participants with a CD4 count >100, 50–100,
and <50 cells/ml, and those severely ill.
Entire cohort LAM (n = 877) No LAM (n = 824) p-Valuea
Yes % (n) No % (n) Yes % (n) No % (n)
Dyspnoea 13.1 (115) 86.9 (762) 13.1 (108) 86.9 (716) 0.990
Night sweats 9.4 (82) 90.6 (795) 9.5 (78) 90.5 (746) 0.935
Pain 14.3 (125) 85.7 (751) 12.9 (106) 87.1 (718) 0.398
Hemoptysis 1.0 (9) 99.0 (868) 0.7 (6) 99.3 (816) 0.514
CD4 >100 cells/ml LAM (n = 393) No LAM (n = 390) p-Valuea
Yes % (n) No % (n) Yes % (n) No % (n)
Dyspnoea 11.9 (47) 88.1 (346) 13.6 (53) 86.4 (337) 0.494
Night sweats 10.2 (40) 89.8 (353) 9.2 (36) 90.8 (354) 0.654
Pain 14.5 (57) 85.5 (336) 11.0 (43) 89.0 (347) 0.145
Hemoptysis 1.2 (5) 98.8 (388) 0.7 (2) 99.3 (387) 0.260
CD4 50–100 cells/ml LAM (n = 124) No LAM (n = 150) p-Valuea
Yes % (n) No % (n) Yes % (n) No % (n)
Dyspnoea 13.7 (17) 86.3 (107) 14.7 (22) 85.3 (128) 0.843
Night sweats 6.5 (8) 93.5 (116) 9.3 (14) 90.7 (136) 0.382
Pain 8.0 (10) 92.0 (114) 11.2 (23) 88.8 (127) 0.066
Hemoptysis 0.8 (1) 99.2 (123) 0 100 (150) 0.271
CD4 <50 cells/ml LAM (n = 298) No LAM (n = 241) p-Valuea
Yes % (n) No % (n) Yes % (n) No % (n)
Dyspnoea 12.1 (36) 87.9 (262) 12.1 (26) 87.9 (215) 0.640
Night sweats 9.1 (27) 90.9 (271) 9.9 (24) 90.1 (217) 0.723
Pain 14.8 (44) 85.2 (253) 13.3 (32) 86.7 (209) 0.611
Hemoptysis 0.7 (2) 99.3 (295) 1.6 (4) 98.4 (237) 0.279
Severely ill LAM (n = 344) No LAM (n = 315) p-Valuea
Yes % (n) No % (n) Yes % (n) No % (n)
Dyspnoea 11.6 (40) 88.4 (304) 18.1 (57) 91.9 (258) 0.019
Night sweats 8.7 (30) 91.3 (314) 10.8 (34) 89.2 (281) 0.369
Pain 14.3 (48) 85.7 (295) 19.7 (62) 80.3 (253) 0.051
Hemoptysis 0.9 (3) 90.1 (341) 1.0 (3) 99.0 (311) 0.911
LAM, lipopolysaccharide lipoarabinomannan.
a Chi-square test.Readmission
In patients receiving adjuvant LAM, there was no reduction in
the frequency of readmission in the entire cohort or in the
subgroups (CD4 cells >100 cells/ml, 50–100 cells/ml, and <50 cells/
ml, and severely ill patients). The aforementioned results are
presented in Table 4.
LAM grade
Higher LAM grade (grades 4 and 5) was associated with lower
use of ultrasound (p = 0.001), lower Karnofsky performance score
(p = 0.005), lower CD4 cell count (p = 0.001), and shorter time to
culture positivity (p = 0.005). The aforementioned results are
presented in Table 5 and Figure 2. There was no significant
difference in time to death in patients with low versus high LAM
grade (p = 0.647). A multivariable analysis for variables associated
with high positive LAM grade (grades 4 and 5) is presented in
Table 6.
Discussion
The aim of this study was to determine whether adjunctive LAM
testing has benefits other than a mortality benefit. However, it was
found that adjuvant LAM did not reduce the number of diagnostic
sputum samples requested or the need for additional imaging and
had no impact on hospital readmission. Adjunctive LAM was
associated with a more rapid rate of disease resolution (dyspnoea)
in the severely ill subgroup, and higher LAM grade was associated
with prognostication (factors known to be associated with
mortality).
In patients receiving adjunctive LAM testing, there was no
reduction in usage of ultrasound or CT scanning. This remained so
even when stratified by country (South Africa was the greatest userTable 4
Patient readmission for those who did and did not receive adjunctive LAM testing.
No LAM Adjunctive LAM p-Value
Entire cohort 76/1195 (6%) 95/1162 (8%) 0.1335
CD4 cells >100 11/519 (2%) 12/462 (3%) 0.0672
CD4 cells 50–100 10/205 (5%) 12/200 (6%) 0.6518
CD4 cells <50 29/421 (7%) 30/446 (7%) 0.8317
Severely ill 26/50 (52%) 41/54 (76%) 0.8253
LAM, lipopolysaccharide lipoarabinomannan.
Table 5
Relationships between LAM grade and CD4 cell count, weight, smear result, previous TB, Karnofsky performance score, mortality, TBscore, and ultrasound and computed
tomography usage.
Low positive grade (1–3)
n = 186




<50 85 (52.2%) 59 (75.6%)
50–100 28 (17.2%) 11 (14.1%)
>100 50 (30.7%) 8 (10.3%)
Weight 0.32
50 95 (51.1%) 36 (44.4%)
>50 91 (48.9%) 45 (55.6%)
Smear result 0.01
Negative 92 (60.5%) 32 (42.7%)
Positive 60 (39.5%) 43 (57.3%)
Previous TB 0.49
No 147 (79.0%) 67 (82.7%)
Yes 39 (21.0%) 14 (17.3%)
Mean Karnofsky score 51.3 (20–90) 46.7 (20–90) 0.005
Mortality 0.238
Dead 48 (27.3%) 27 (34.6%)
Alive 128 (72.7%) 51 (65.4%)
TBscore 80 44 0.772
Ultrasound (yes) 64 (39.3%) 14 (18.4%) 0.001
CT (yes) 3 (1.7%) 1 (1.3%) 0.830
LAM, lipopolysaccharide lipoarabinomannan; TB, tuberculosis; CT, computed tomography.
Figure 2. Time to tuberculosis culture positivity in participants with low versus high LAM grade.
Table 6
Multivariable analysis for variables associated with high positive LAM grades
(grades 4 and 5).
OR p-Value 95% CI
CD4 cell count category 0.6214 0.083 0.3626–1.0649
Smear result 1.9582 0.037 1.0422–3.6795
Karnofsky score 0.9789 0.066 0.9569–1.0014
Ultrasound 0.3316 0.013 0.1391–0.7902
LAM, lipopolysaccharide lipoarabinomannan; OR, odds ratio; CI, confidence
interval.
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specifically identify the site/sites of TB and imaging may add
clinically useful additional information. Indeed, imaging informs
about the site of TB, which often affects downstream management
including the selection of drugs, dose, and use of adjunctive
steroids (e.g., TB pericarditis and TB meningitis, which may requiredrainage or surgical intervention, and drug selection, dosage, and
duration may differ with intracranial TB) (Marx and Chan, 2011).
Furthermore, if the patient has neurological signs, a CT scan of the
brain may determine whether there is TB-associated hydrocepha-
lus or other space-occupying lesions (Marx and Chan, 2011;
Thwaites et al., 2009). Indeed, the British Infection Society
recommends that every patient with intracranial TB should have
a CT brain scan (Thwaites et al., 2009). South Africa performed far
greater numbers of CT scans than the other study sites, probably
because of greater availability of imaging resources in a middle-
income country. Secondly, imaging is often required to rule out
other diseases that may co-exist with TB or to exclude other
differential diagnoses, e.g., lymphoma (Heller et al., 2010). In short,
adjunctive LAM does not differentiate between pulmonary and
extrapulmonary TB, and radiological investigation is still required,
where clinically indicated.
There are several other possible reasons for the failure to
demonstrate a reduction in healthcare utilization. Firstly, we did
42 P. Naidoo et al. / International Journal of Infectious Diseases 79 (2019) 37–43not expressly collect the data and it was not an a priori primary or
secondary aim of the parent study. Secondly, as outlined above,
physicians may have requested investigations for other clinical
reasons including ruling out or ruling in other opportunistic
infections, or other clinical indications. In addition, at the time of
the study, the mortality benefit of LAM was unknown and so
clinicians were more likely to continue their normal practices
regardless of LAM.
In patients receiving adjuvant LAM, there was no reduction in
the frequency of readmission in the entire cohort or in the
subgroups. Speculative reasons for this finding include the short
study duration, the relatively small number of patients who were
readmitted, poor health-seeking behaviour, and management of
these patients at non-trial centres.
During follow-up, there were significantly fewer patients with
dyspnoea in the severely ill group receiving adjuvant LAM. This
may be due to the possibly higher rate of extrapulmonary rather
than pulmonary involvement in those with advanced HIV, or it may
be a chance finding, as adjunctive LAM was not associated with a
reduction in other symptoms, i.e., night sweats, pain, and
haemoptysis. It is challenging to compare these results with
published data because such a study has not been performed
previously. Bark et al. (2011) investigated symptoms in a
previously published international phase 3 trial of TB therapy in
394 ambulatory HIV-uninfected subjects (Johnson et al., 2009).
Bark et al. (2011) found that self-reported symptoms at baseline
included dyspnoea (30%), cough (81%), and fever (51%). After the
first 2 months of treatment, the proportion of subjects with
symptoms declined by 94% for fever, 59% for cough, 77% for chest
pain, 94% for sweats, and 81% for dyspnoea. The reduction of
dyspnoea mirrors the result in the present study. In patients
receiving adjunctive LAM testing, a reduction in TB symptoms may
be attributed to appropriate patients receiving correct and timely
anti-TB therapy.
Higher LAM grade (grades 4 and 5) correlated with poor
prognostic characteristics (lower Karnofsky score and lower CD4
cell count). This may assist with prognostication and targeting
such patients (more likely to die) with more aggressive therapy
and follow-up. This requires further exploration and investigation.
The findings of this study are aligned with those of Kerkhoff et al.
(2014), who found that in “patients with HIV-associated TB,
concentrations of LAM in urine were strongly associated with a
range of poor prognostic characteristics known to be associated
with mortality risk.” Drain et al. (2015) showed that there was a
significantly greater mortality risk in patients with a LAM grade of
2 after 2 months of anti-TB therapy. However the study, which
had a limited sample size, did not determine the effect of LAM
grade on prognosis before the initiation of anti-TB therapy. No
other published study that has investigated the prognostic value of
LAM grade could be identified.
There are several limitations to this study. This was a post-hoc
analysis and thus the results must be interpreted with caution. The
study sites had heterogeneous patients with differing severity of
disease. Furthermore, the study duration was 8 weeks; a longer
duration study may have better captured readmission rates. It is
thus possible that adjunctive LAM may still have beneficial effects
on healthcare utilization. A major limitation is the absence of
capturing antibiotic utilization. There is currently a focus on
antibiotic stewardship and it would have been useful to know
whether patients receiving adjuvant LAM would have had a
reduction in the utilization of antibiotics. It is likely this might be
the case, as a positive LAM test would negate the use of empiric
antibiotic therapy. Further studies are required to address this
question.
In conclusion, although in the parent study adjunct LAM was
associated with a mortality benefit, in the subgroup analysis nobenefit could be demonstrated with respect to the number of
diagnostic sputum samples requested, the use of additional
imaging, or hospital readmission rates. However, given the
limitations of the study, further appropriately designed and
prospective studies are required to determine the effect of adjunct
urine LAM on the utilization of healthcare resources.
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